Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$38.78−0.48 (-1.22%)
Close on Nov 17, 2026Market cap $3.76BP/E –Yield –
Xenon Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Xenon Pharmaceuticals's total assets was $1.30B at Jun 30, 2026. For fiscal 2025 it was $633.16M, down 20.7% from the year before. Over ten years it grew 25.8% a year on average. The highest annual figure on record is $964.80M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $633.16M | -20.7% |
| FY2024 | Dec 31, 2024 | $798.14M | -17.3% |
| FY2023 | Dec 31, 2023 | $964.80M | +27.9% |
| FY2022 | Dec 31, 2022 | $754.15M | +31.8% |
| FY2021 | Dec 31, 2021 | $572.01M | +202.4% |
| FY2020 | Dec 31, 2020 | $189.19M | +28.1% |
| FY2019 | Dec 31, 2019 | $147.70M | +20.6% |
| FY2018 | Dec 31, 2018 | $122.43M | +165.4% |
| FY2017 | Dec 31, 2017 | $46.12M | -31.7% |
| FY2016 | Dec 31, 2016 | $67.49M | +5.5% |
| FY2015 | Dec 31, 2015 | $63.95M | -26.8% |
| FY2014 | Dec 31, 2014 | $87.42M | +60.4% |
| FY2013 | Dec 31, 2013 | $54.49M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.30B | +92.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.39B | +86.6% |
| Q4 FY2025 | Dec 31, 2025 | $633.16M | -20.7% |
| Q3 FY2025 | Sep 30, 2025 | $607.84M | -27.3% |
| Q2 FY2025 | Jun 30, 2025 | $674.28M | -23.7% |
| Q1 FY2025 | Mar 31, 2025 | $743.28M | -19.1% |
| Q4 FY2024 | Dec 31, 2024 | $798.14M | -17.3% |
| Q3 FY2024 | Sep 30, 2024 | $835.90M | +24.6% |
| Q2 FY2024 | Jun 30, 2024 | $884.01M | +29.1% |
| Q1 FY2024 | Mar 31, 2024 | $919.02M | +27.7% |
| Q4 FY2023 | Dec 31, 2023 | $964.80M | +27.9% |
| Q3 FY2023 | Sep 30, 2023 | $671.09M | -13.5% |
| Q2 FY2023 | Jun 30, 2023 | $684.90M | -15.2% |
| Q1 FY2023 | Mar 31, 2023 | $719.87M | +29.0% |
| Q4 FY2022 | Dec 31, 2022 | $754.15M | +31.8% |
| Q3 FY2022 | Sep 30, 2022 | $775.81M | +193.5% |
| Q2 FY2022 | Jun 30, 2022 | $807.38M | +193.9% |
| Q1 FY2022 | Mar 31, 2022 | $558.06M | +92.0% |
| Q4 FY2021 | Dec 31, 2021 | $572.01M | +202.4% |
| Q3 FY2021 | Sep 30, 2021 | $264.35M | +32.8% |
| Q2 FY2021 | Jun 30, 2021 | $274.71M | +30.4% |
| Q1 FY2021 | Mar 31, 2021 | $290.67M | +22.6% |
| Q4 FY2020 | Dec 31, 2020 | $189.19M | +28.1% |
| Q3 FY2020 | Sep 30, 2020 | $199.13M | +101.3% |
| Q2 FY2020 | Jun 30, 2020 | $210.68M | +99.0% |
| Q1 FY2020 | Mar 31, 2020 | $237.04M | +106.9% |
| Q4 FY2019 | Dec 31, 2019 | $147.70M | +20.6% |
| Q3 FY2019 | Sep 30, 2019 | $98.90M | -24.2% |
| Q2 FY2019 | Jun 30, 2019 | $105.89M | +61.8% |
| Q1 FY2019 | Mar 31, 2019 | $114.55M | +203.3% |
| Q4 FY2018 | Dec 31, 2018 | $122.43M | +165.4% |
| Q3 FY2018 | Sep 30, 2018 | $130.46M | +181.4% |
| Q2 FY2018 | Jun 30, 2018 | $65.44M | +20.7% |
| Q1 FY2018 | Mar 31, 2018 | $37.76M | -37.9% |
| Q4 FY2017 | Dec 31, 2017 | $46.12M | -31.7% |
| Q3 FY2017 | Sep 30, 2017 | $46.36M | -36.8% |
| Q2 FY2017 | Jun 30, 2017 | $54.23M | – |
| Q1 FY2017 | Mar 31, 2017 | $60.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $67.49M | – |
| Q3 FY2016 | Sep 30, 2016 | $73.37M | – |
See a number that looks wrong?